funder-graph › Recipients
Who funds Kernal Biologics Inc
EIN 81-3590890
Kernal Biologics Inc (EIN 81-3590890) was named as a grant recipient by 1 funder in 4 grants paid totaling $219,805 in tax years 2019–2022, as reported on the funders' Forms 990-PF and 990 Schedule I. Each edge was resolved to this EIN at the match tier shown. Dataset version 2026.09.0, built 2026-09-03.
Grants received
$219,805
4 grants paid
Funders
1
distinct grantmakers
Tax years
2019–2022
as reported by funders
Funders
| Funder | State | Match | Grants | Total paid | Latest year |
|---|---|---|---|---|---|
| Center for the Advancement of Science in Space Inc 27-5410763 | FL | A | 4 | $219,805 | 2022 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Grants
The 4 most recent grants naming this organization.
| Tax year | Funder | Recipient | Match | Amount | Type | Purpose | Source filing |
|---|---|---|---|---|---|---|---|
| 2022 | Center for the Advancement of Science in Space Inc | Kernal Biologics Inc Cambridge, MA | A | $4,025 | paid | THIS PROJECT SEEKS TO TEST CANDIDATE MESSENGER RNA MOLECULES TO IDENTIFY WHICH ARE BEST ABLE TO DISTINGUISH BETWEEN CANCER CELLS AND HEALTHY CELLS IN THE STRESSFUL MICROGRAVITY ENVIRONMENT, TOWARD THE DEVELOPMENT OF NEW IMMUNOTHERAPY DRUGS TO TREAT LEUKEMIA. | 202340449349300709 |
| 2021 | Center for the Advancement of Science in Space Inc | Kernal Biologics Inc Cambridge, MA | A | $28,709 | paid | THIS PROJECT SEEKS TO TEST CANDIDATE MESSENGER RNA MOLECULES TO IDENTIFY WHICH ARE BEST ABLE TO DISTINGUISH BETWEEN CANCER CELLS AND HEALTHY CELLS IN THE STRESSFUL MICROGRAVITY ENVIRONMENT, TOWARD THE DEVELOPMENT OF NEW IMMUNOTHERAPY DRUGS TO TREAT LEUKEMIA. | 202210549349301556 |
| 2020 | Center for the Advancement of Science in Space Inc | Kernal Biologics Inc Cambridge, MA | A | $139,430 | paid | THIS PROJECT SEEKS TO TEST CANDIDATE MESSENGER RNA MOLECULES TO IDENTIFY WHICH ARE BEST ABLE TO DISTINGUISH BETWEEN CANCER CELLS AND HEALTHY CELLS IN THE STRESSFUL MICROGRAVITY ENVIRONMENT, TOWARD THE DEVELOPMENT OF NEW IMMUNOTHERAPY DRUGS TO TREAT LEUKEMIA. | 202140579349300724 |
| 2019 | Center for the Advancement of Science in Space Inc | Kernal Biologics Inc Cambridge, MA | A | $47,641 | paid | THIS PROJECT SEEKS TO TEST CANDIDATE MESSENGER RNA MOLECULES TO IDENTIFY WHICH ARE BEST ABLE TO DISTINGUISH BETWEEN CANCER CELLS AND HEALTHY CELLS IN THE STRESSFUL MICROGRAVITY ENVIRONMENT, TOWARD THE DEVELOPMENT OF NEW IMMUNOTHERAPY DRUGS TO TREAT LEUKEMIA. | 202020379349300642 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Recipient matching for this dataset version has not yet completed its independent precision check. Tier A rows carry the EIN the filer reported; tiers B–D are inferred and should be read as leads until the check is published on the methodology page.
Derived from IRS Form 990-PF and Form 990 Schedule I e-file XML filed by the funders shown; this organization's identity from the IRS Exempt Organizations Business Master File. Dataset version 2026.09.0, built 2026-09-03. The rows as Parquet: manifest.
The same organization elsewhere in the program: exempt status and filing health · federal awards · grant guidance · open opportunities.
This is informational only, derived from public data on the dates shown. It is not an eligibility determination, and not legal, tax, or accounting advice. Verify against the official source before relying on it.